| Trial ID: | L6073 |
| Source ID: | NCT02383238
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content
|
| Acronym: |
Dapa
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Microcirculation, To analyse the effects after 6 weeks of treatment with dapagliflozin on retinal capillary flow (given as AU) as the key measurement of vascular remodeling in the microcirculation compared to placebo., 6 weeks | Secondary: Macrovascular circulation, To analyse the effects after 6 weeks of treatment with dapagliflozin on central (aortic) systolic pressure, central (aortic) pulse pressure and augmentation pressure, on retinal capillary flow after flicker light exposure, parameters that all are determined by pulse wave reflection (i.e. arterial wall properties) in the arterial tree compared to placebo., 6 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Erlangen-Nürnberg Medical School
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
59
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2014-03
|
| Completion Date: |
2015-10
|
| Results First Posted: |
|
| Last Update Posted: |
2018-05-11
|
| Locations: |
University Erlangen-Nuernberg, Erlangen, 91054, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT02383238
|
